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Abstract
Bladder cancer is one of the leading causes of cancer-related death in men, however, there
was only limited effective treatment for invasive bladder cancer. DAPK1 has been shown to
play important role in apoptosis and autophagy to suppress cancer progression. Previous
results have shown that DAPK1 promoter was hypermethylated in the majority of bladder
cancer specimens, however, the prognostic significance of DAPK1 in bladder cancer has
yet to be demonstrated. In the present study, we found that DAPK1 expression was nega-
tively associated with tumor stage and a low level expression of DAPK1 in bladder cancer
specimens were associated with shorter survival in bladder cancer patients in 3 independent
bladder cancer datasets (n = 462). Further investigation showed that FGFR3 knockdown
resulted in downregulation of DAPK1 in bladder cancer cell line, suggesting that FGFR3
may be an upstream factor of DAPK1. Further analysis of the 3 independent bladder cancer
datasets have identified ACOX1, UPK2, TRAK1, PLEKHG6 and MT1X genes had their
expression significantly correlated with that of DAPK1. Knockdown of DAPK1 in bladder
cancer T24 cells resulted in downregulation of ACOX1, UPK2 and TRAK1. Interestingly,
TRAK1, by itself, was a favorable prognostic marker in the 3 independent bladder cancer
datasets. Importantly, by using connectivity mapping with DAPK1-associated gene signa-
ture, we found that vemurafenib and trametinib could possibly reverse DAPK1-associated
gene signature, suggesting that inhibition of Raf/MEK pathway may be a potential therapeu-
tic approach for bladder cancer. Indeed, treatment of vemurafenib in T24 bladder cancer
cells resulted in upregulation of DAPK1 confirming our connectivity mapping, while knock-
down of DAPK1 resulted in reduced sensitivity towards inhibition of Braf signaling by vemur-
afenib. Together, our results suggest that DAPK1 is an important prognostic marker and
therapeutic target for bladder cancer and have identified possible therapeutic agents for
future testing in bladder cancer models with low DAPK1 expression.
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Introduction
Bladder cancer is the 6th most common cancer and the 9th leading cause of cancer-related
death worldwide in men [1]. Although the understanding of bladder cancer has improved dra-
matically in the last decade, novel treatment that could potentially improve patient outcome
has just recently been discovered [2–4]. Bladder cancer can be divided into muscle invasive
and non-muscle invasive, in which muscle invasive bladder cancer has poor prognosis com-
pared to non-muscle invasive bladder cancer [5]. Recent advances in expression profiling sug-
gest that bladder cancer can be further divided into various subtypes, which may require
different disease management and treatment in the future, depending on its molecular charac-
teristics [6].
Death-Associated Protein Kinase 1 (DAPK1) is a member of the serine/threonine kinases
that could act as a tumor suppressor in relation to its function to regulate apoptosis and autop-
hagy [7]. We have previously shown that a germ line mutation in death domain of DAPK1
could diminish its function in promoting apoptosis [8] and the protein stability of DAPK1 is
regulated by both the TSC1 [9] and its own splice variant [10], suggesting that DAPK1 expres-
sion was post-translationally regulated. On the other hand, data were also available showing
that DAPK1 is regulated at the transcriptional level via its promoter methylation. DAPK1 pro-
moter has been shown to be hypermethylated in bladder cancer [11, 12]. Demethylating agents
have been shown to reverse the hypermethylation status of DAPK1 promoter leading to re-
expression of DAPK1 mRNA resulting in retarded growth of bladder cancer cell lines [13]. In
a study with 34 bladder cancer samples, the correlation between DAPK1 mRNA expression
and tumor staging and grading could not be established [14].
In this study, we aimed to investigate the prognostic significance of DAPK1 expression in
bladder cancer, identify genes that are co-regulated with DAPK1 in bladder cancer and iden-
tify small molecules that could reverse the DAPK1-associated gene signature.
Materials and methods
Extraction of clinical and microarray gene expression data from bladder
cancer patient datasets
A search was performed using “bladder cancer or Urothelial cancer in Gene Expression Omni-
bus database. Four datasets with more than 130 cancer patients in a single microarray plat-
form, GSE13507 (n = 165) [15, 16], GSE32548 (n = 131; Survival data was not available in this
dataset) [17], GSE32894 (n = 308) [18] and GSE48277 (n = 142) [19], were identified (S1 Fig).
In addition, another dataset GSE41035 with modification of FGFR3 gene in bladder cancer
dataset was also used in the current study to test the association between FGFR3 and DAPK1
[20]. The GEO website has standardized URLs for its individual dataset, the files in gzip format
were unzipped to the tab-delimited text format, which contain detailed clinical information
for statistical analysis. R scripting was used to extract the expression values of probesets from
genes of interest and the clinical data from the data matrixes downloaded from the GEO data-
base was then combined for analysis.
Statistical analysis
All statistical analyses were performed using SPSS19.0. The associations between gene expres-
sion and clinicopathological parameters were tested by ANOVA with post-hoc Bonferroni test
for multiple comparisons. Tumors with T-stage of T2 or above were classified as having a high
T-stage. The associations between gene expression and survival were estimated by Kaplan-
Meier survival analysis and statistically tested by log-rank test. The associations between
DAPK1 in bladder cancer
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expression levels of genes were analyzed by Spearman’s rank test. Univariate Cox-regression
was used to test the correlations between gene expression levels and survival.
Identification of DAPK1 co-expressing genes
Patients were stratified into four groups based on the expression levels of DAPK1. The gene
expression patterns of patients in DAPK1-low subgroup and those in the DAPK1-high sub-
group were compared. Probesets that were differentially expressed between these two sub-
groups were identified by 2-sample Welch’s T-test. This test was used to avoid the type I error
due to unequal variances of the values of probesets between subgroups. Briefly, a Welch’s t test
was applied to each probeset corresponding to a certain gene in the data matrix using our own
Java application MyStats. P values and the differential expression in fold changes for all the
probesets were generated as tab-delimited worksheets of Excel for further analysis. The genes
were ranked based on the p value for all the probesets available for a particular gene and the
top 5 genes were extracted from the GEO database for further analysis.
Identification of potential therapeutic small molecule for bladder cancer
patients overexpressing DAPK1 through connectivity mapping
Gene expression connectivity mapping was performed using Statistically Significant Connec-
tion’s Map (sscMap) to identify candidate small molecule compounds that may reverse the
reduced expression of DAPK1 and its associated gene expression signature [21–23]. The rele-
vant probes were input to the Java application sscMap [23] as a query signature, and its associ-
ation with the 6000 gene expression profiles generated by treating cancer cells with over 1000
small molecules were compared. The gene signature perturbation procedure, which increases
the specificity of the output results, was applied as previously described [24]. All the small
molecular compounds that were negatively associated with the input were sorted and ranked
by their p-value, perturbation stability and standardized connection score. The p-value that
was considered significant was set at a stringent threshold (p = 1/1309), ensuring that the
results generated by sccMap would yield a maximum of one false positive small molecule over
the 1309 small molecules tested in the sccMap [24].
Construction of stable cell lines
Human transitional carcinoma cell lines T24 derived from bladder epithelial tissue was pur-
chased from the Institute of Biochemistry and Cell Biology at the Chinese Academy of Sciences
(Shanghai, China). T24 cell lines was maintained in RPMI 1640 (Invitrogen Corp., Carlsbad,
California) containing 10% fetal bovine serum (FBS) (Equitech-Bio, Ingram, Texas), 100
units/ml penicillin G and 100 μg/ml streptomycin (Invitrogen Corp.). Cells were incubated at
37˚C in a humidified incubator with 5% CO2. To create DAPK-knockdown bladder cancer
cells, lentiviral infection was performed. Briefly, control and DAPK-knockdown cell lines were
established utilizing lentivirus particles containing scramble shRNA (SHC016V) or DAPK-tar-
get shRNA (SHCLNV-NM_004938) from Sigma (USA); Sequences of the shRNA are listed in
S1 Table
Bladder cancer cells were seeded onto plates and infected with lentiviral particles in 1640
containing 8 μg/ml polybrene (Sigma). One day after the incubation, the media containing len-
tivirus was changed with the growth media, and the cells were incubated for another day.
Puromycin (Invitrogen) at 0.4 μg/ml was added to each well to select for cells efficient for
DAPK depletion. The shRNA sequences are shown in S1 Table.
DAPK1 in bladder cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0175290 April 7, 2017 3 / 18
Western blot
Cells were homogenized in 100~200μl of radioimmunoprecipitation assay (RIPA) lysis buffer
(Beyotime, Shanghai, China) containing protease inhibitors (Roche, Basel, Switzerland) and
placed at 4˚C for 30 mins. Protein concentrations were measured by Micro BCA protein assay
kit (Pierce Biotechnology). Protein was resolved on sodium dodecyl sulfate-polyacrylamide
(SDS) gel and subsequently transferred to a nitrocellulose membrane (Life Technologies,
Carlsbad,CA, USA). The nitrocellulose membrane was then incubated with the primary anti-
bodies and with the horseradish peroxidase (HRP)-conjugated goat anti-rabbit or anti-mouse
secondary antibodies, with phosphate buffer saline (PBS) buffer washes in between. The anti-
DAPK and anti-GAPDH antibodies were from Cell Signaling Technology (Beyotime, Shang-
hai, China). The secondary antibodies were from Sigma-Aldrich (St. Louis, MO).
SRB assay
Cells were first seeded in 6cm dishes and allowed to grow for 3 days. Then for SRB assay, stable
cell lines were seeded at a density of 2500 cells/well into 96-well plates respectively. Next cells
continued to grow with vemurafenib for another 72h. After culture, total cell amount were
detected using SRB assay. At the end of the respective incubation time, cells were fixed by the
addition of 10% trichloroacetic acid and incubated for 1 hour at 4˚C. Plates were washed in
tap water five times and allowed to dry. Cellular protein was stained by adding 4% SRB in 1%
acetic acid and incubated at room temperature for 30 minutes. Excess SRB was removed by
washing the wells with 1% acetic acid and remaining SRB was solubilized in 10 mM Tris-base
unbuffered. Absorbance was determined on a microplate reader(BiOTeK, USA) at a wave-
length of 510 nm. Data were obtained from three wells per condition.
RNA extraction, transcription and real-time PCR
The mRNA from cell lines was extracted using the EastepTM Total RNA Extraction Kit (Pro-
mega, Beijing, China) and reverse transcribed using the GoScript™ Reverse transcription sys-
tem (Promega, Madison, USA) according to the manufacturers’ instruction. Amplification
reactions were performed in ABI 7500 real-time PCR system (ABI, America), and PCR was
performed using GoTaqTM qPCR Master Mix according to the manufacturers’ instruction.
The Real-Time PCR primers for DAPK1, UPK2, TRAK1, ACOX1 and Glyceraldehyde-
3-phosphate dehydrogenase are listed on S2 Table. PCR reaction conditions were as follows:
95˚C for 2 min, 40 cycles at 95˚C for 15 s and 60˚C for 1 min. The cDNA from cells were used
as positive control and standard curve.
Results
The association between DAPK1 mRNA expression and
clinicopathological parameters
There were 165 bladder cancer specimens with available clinicopathological and survival infor-
mation in the GSE13507 bladder cancer patient cohort. DAPK1 expression was significantly
higher in bladder cancer with a Ta or T1 stage compared to those with T2 stage or above
(p = 0.012; Fig 1A). Similarly, in GSE32548 dataset, there were 131 bladder cancer patients
with available clinicopathological information with one patients had missing T-stage informa-
tion. In this patient cohort, DAPK1 expression was significantly lower in bladder cancer speci-
mens with a T2 stage or above compared to those with Ta or T0 stage (p = 0.011; Fig 1B).
Similar results were also observed for GSE32894 bladder cancer cohort, in which, there were
308 bladder cancer patients with available clinicopathological and 306 of these patients had
DAPK1 in bladder cancer
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available information on their T-stage. In this patient cohort, DAPK1 expression was signifi-
cantly lower in bladder cancer specimens with a T2 stage or above compared to those with Ta
or T1 stage (p = 0.002; Fig 1C). Lastly, for the 142 patients with available information on stag-
ing in GSE48277, a significant association between high DAPK1 mRNA expression and Ta/T1
stage was also observed (p< 0.001; Fig 1D).
However, although only available in GSE13507 patient cohort, low level expression of
DAPK1 was significantly associated with muscle invasive bladder cancer specimens compared
to non-muscle invasive bladder cancer specimens (p = 0.008; Fig 2A). Molecular signature was
available in GSE32894 dataset, and we also found that DAPK1 expression was significantly
lower in the more aggressive subtypes of bladder cancer, Urobasal B (MS2b2.1) and SCC-like
(MS2b2.2) subtypes (p< 0.001; Fig 2B).
Fig 1. The association between mRNA expression of DAPK1 and T-stage. Error bar plots for DAPK1 expression against high (T-
stage 2) or low (Ta or T1-stage) in bladder cancer cohort (A) GSE13507 (n = 165), (B) GSE32548 (n = 130), (C) GSE32894 (n = 306) and
(D) GSE48277 (n = 142). We also tested whether DAPK1 expression was associated with other clincopathological parameters, and we found
that DAPK1 expression was not associated with tumor grading, N-stage and M-stage in all the four datasets analyzed in the current study.
https://doi.org/10.1371/journal.pone.0175290.g001
DAPK1 in bladder cancer
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The association between DAPK1 mRNA expression and patient survival
Three out of the four datasets analyzed in the current study had available information on
patient survival data. The association between DAPK1 expression and patient survival was
tested by Kaplan-Meier analysis compared by log-rank test. In GSE13507, we found that
patients whose tumors had the top 25% expression of DAPK1 had a significantly longer dis-
ease-specific survival time (mean = 118 months, 95% CI = 109–128 months) compared to
other patients whose tumors expressed a lower level of DAPK1 (mean = 104, 95% CI = 94–115
months, p = 0.047; Fig 3A). In GSE32894, patients whose tumors expressed DAPK1 at bottom
25% level had a shorter survival time (mean = 75 months, 95% CI = 64–75 months) compared
to those patients whose tumors expressed DAPK1 at a higher level (mean = 101 months, 95%
CI = 96–106 months, p = 0.004; Fig 3B). In the 73 patients whose survival data were available
in GSE48277 patient cohort, patients whose tumors had DAPK1 expression at the bottom 25%
percentile had a significantly shorter disease-specific survival time (mean = 48 months, 95%
CI = 29–67 months) compared to those patients whose tumors had a higher expression of
DAPK1 (mean = 103 months, 95% CI = 77–129 months, p = 0.035; Fig 3C). When combined
the three datasets together, we found that patients whose tumors expressed DAPK1 at bottom
25% percentile had a significant shorter survival time (mean = 92.544; 95% CI = 79–106) com-
pared to those patients whose tumors expressed DAPK1 at a higher level (mean = 146; 95%
CI = 137–154; p = 0.002; Fig 3D). By Cox regression analysis, we found that patients whose
tumors expressed DAPK1 at a higher level had a lower risk of death or progression. Compar-
ing to< 25% DAPK1 expressors, 25% - 50% DAPK1 expressors had a 38% lower risk
(HR = 0.62, 95% CI = 0.36–1.05, p = 0.075), 50% - 75% DAPK1 expressors had a 53% lower
risk (HR = 0.47, 95% CI = 0.27–0.83, p = 0.009), while > 75% DAPK1 expressors had a 63%
lower risk (HR = 0.37, 95% CI = 0.20–0.67, p = 0.001).
The association between FGFR3 and DAPK1 expression
Aberrant activation of FGFR3 by overexpression of activation mutation is common in bladder
cancer and it has been shown to modulate lipid metabolism in order to maintain tumor
Fig 2. The association between mRNA expression of DAPK1 with muscle invasiveness and gene signature subtype. (A) An error bar plot
for DAPK1 expression in non-muscle invasive and muscle invasive types of bladder cancer cohort GSE13507. (B) A box plot for DAPK1
expression in bladder cancer with different molecular subtypes
https://doi.org/10.1371/journal.pone.0175290.g002
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growth and survival [20]. Using microarray data generated from bladder cancer cell line,
RT112, with inducible knockdown of FGFR3 from three different shFGFR3 sequences, we
found that DAPK1 expression was upregulated by knockdown of FGFR3 in inducible condi-
tions for all the three different shFGFR3 sequences (p< 0.001; Fig 4A). In GSE48277, where
both FGFR3 expression and mutational status were available, we further analyzed the relation-
ship between FGFR3 mutation and expression, and DAPK1 expression. Although the expres-
sion level of DAPK1 was not significantly different between FGFR3 wild-type and mutation
group when FGFR3 was expressing at a high level, DAPK1 expression was significantly lower
Fig 3. The association between mRNA expression of DAPK1 and bladder cancer patient survival. Kaplan-Meier plots for survival with different level of
DAPK1 expression in (A) GSE13507 (n = 165; all patients with survival data available), (B) GSE32894 (n = 224; patients with available survival data), (C)
GSE48277 (n = 73; patients with available survival data) and (D) combined cohort.
https://doi.org/10.1371/journal.pone.0175290.g003
DAPK1 in bladder cancer
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in the specimens with FGFR3 activation mutation compared to those without the mutation
when FGFR3 was expressing at a low level (p< 0.001; Fig 4B). Our results suggest that in a
Fig 4. The association between FGFR3 and mRNA expression of DAPK1. (A) An error bar plot for
DAPK1 mRNA expression in bladder cancer cell lines, RT112, with different expression of FGFR3 modulated
through doxycyclin inducible shRNA knockdown in GSE41035. (B) A box plot for DAPK1 mRNA expression
against FGFR3 mutational status in bladder cancer specimens with low level expression of FGFR3 mRNA.
https://doi.org/10.1371/journal.pone.0175290.g004
DAPK1 in bladder cancer
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background of low FGFR3 expression, its activating mutation may play a significant role in
suppressing the expression of DAPK1 in bladder cancer.
The identification of DAPK1 co-regulated gene targets
By stratifying the specimens based on their DAPK1 expression levels, we compared the expres-
sion patterns of genes and identified genes that are differentially expressed between DAP-
K1-high and DAPK1-low subgroups. The top 5 genes that are consistently differentially
expressed in the 3 bladder cancer datasets, GSE13507, GSE32894 and GSE48277, were fur-
ther analyzed. As shown in Tables 1–4, the expression levels of ACOX1, UPK2, TRAK1 and
PLEKHG6 were significantly positively correlated with DAPK1 expression level (p< 0.001),
while the expression level of MT1X was significantly negatively correlated with DAPK1 ex-
pression level (p< 0.001). By univariate cox-regression analysis, we found that patients with a
high level expression of ACOX1, UPK2 and TRAK1, had a 36% (HR = 0.64, 95% CI = 0.42–
0.97, p = 0.036; Fig 5A), 37% (HR = 0.63, 95% CI = 0.42–0.96, p = 0.033; Fig 5B) and 82%
Table 1. GSE13507 dataset (n = 256) DAPK1 Correlation.
DAPK1 ACOX1 UPK2 TRAK1 PLEKHG6 MT1X
Spearman’s rho DAPK1 Correlation Coefficient 1.000 .471** .526** .546** .478** -.519**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
ACOX1 Correlation Coefficient .471** 1.000 .640** .629** .487** -.275**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
UPK2 Correlation Coefficient .526** .640** 1.000 .660** .521** -.467**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
TRAK1 Correlation Coefficient .546** .629** .660** 1.000 .459** -.428**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
PLEKHG6 Correlation Coefficient .478** .487** .521** .459** 1.000 -.467**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MT1X Correlation Coefficient -.519** -.275** -.467** -.428** -.467** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
**. Correlation is significant at the 0.01 level (2-tailed).
https://doi.org/10.1371/journal.pone.0175290.t001
Table 2. GSE32548 dataset (n = 131) DAPK1 Correlation.
DAPK1 ACOX1 UPK2 TRAK1 PLEKHG6 MT1X
Spearman’s rho DAPK1 Correlation Coefficient 1.000 .589** .589** .521** .558** -.529**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
ACOX1 Correlation Coefficient .589** 1.000 .617** .447** .533** -.504**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
UPK2 Correlation Coefficient .589** .617** 1.000 .590** .600** -.658**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
TRAK1 Correlation Coefficient .521** .447** .590** 1.000 .415** -.634**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
PLEKHG6 Correlation Coefficient .558** .533** .600** .415** 1.000 -.485**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MT1X Correlation Coefficient -.529** -.504** -.658** -.634** -.485** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
**. Correlation is significant at the 0.01 level (2-tailed).
https://doi.org/10.1371/journal.pone.0175290.t002
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(HR = 0.28, 95% CI = 0.17–0.46, p< 0.001; Fig 5C) reduction in risk of death or disease-
related event, respectively, in the combined dataset. A high expression of PLEKHG6 was also
associated with shorter survival time but it was not significant (Fig 5D). On the other hand,
patients with a high level expression of MT1X had a significant 2.8-fold increase in risk of
death or disease-related event (HR = 2.83, 95% CI = 1.81–4.41, p < 0.001; Fig 5E) in the com-
bined dataset.
As shown in Fig 6, we found that the expression levels of DAPK1 and TRAK1 were posi-
tively significantly correlated with each other and that a low level expression of TRAK1 was
associated with a poorer survival in the three bladder cancer patient cohorts. Our results show
that TRAK1 expression was significantly associated with both DAPK1 expression and survival
consistently in all the three bladder cancer patient cohorts and suggest that TRAK1 is a favour-
able prognostic marker in bladder cancer.
To confirm the findings from bladder cancer datasets, an in vitro experiment was carried
out. DAPK1 was knocked down in a bladder cancer cell lines, T24 (Fig 7A), and mRNA
Table 4. GSE48277 dataset (n = 142) DAPK1 Correlation.
DAPK1 ACOX1 UPK2 TRAK1 PLEKHG6 MT1X
Spearman’s rho DAPK1 Correlation Coefficient 1.000 .710** .649** .677** .584** -.674**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
ACOX1 Correlation Coefficient .710** 1.000 .626** .629** .562** -.617**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
UPK2 Correlation Coefficient .649** .626** 1.000 .730** .740** -.691**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
TRAK1 Correlation Coefficient .677** .629** .730** 1.000 .590** -.754**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
PLEKHG6 Correlation Coefficient .584** .562** .740** .590** 1.000 -.577**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MT1X Correlation Coefficient -.674** -.617** -.691** -.754** -.577** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
**. Correlation is significant at the 0.01 level (2-tailed).
https://doi.org/10.1371/journal.pone.0175290.t004
Table 3. GSE32894 dataset (n = 308) DAPK1 Correlation.
DAPK1 ACOX1 UPK2 TRAK1 PLEKHG6 MT1X
Spearman’s rho DAPK1 Correlation Coefficient 1.000 .592** .618** .573** .582** -.529**
P value . < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
ACOX1 Correlation Coefficient .592** 1.000 .657** .501** .573** -.502**
P value < 0.001 . < 0.001 < 0.001 < 0.001 < 0.001
UPK2 Correlation Coefficient .618** .657** 1.000 .626** .667** -.595**
P value < 0.001 < 0.001 . < 0.001 < 0.001 < 0.001
TRAK1 Correlation Coefficient .573** .501** .626** 1.000 .563** -.641**
P value < 0.001 < 0.001 < 0.001 . < 0.001 < 0.001
PLEKHG6 Correlation Coefficient .582** .573** .667** .563** 1.000 -.522**
P value < 0.001 < 0.001 < 0.001 < 0.001 . < 0.001
MT1X Correlation Coefficient -.548** -.502** -.595** -.641** -.522** 1.000
P value. < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 .
**. Correlation is significant at the 0.01 level (2-tailed).
https://doi.org/10.1371/journal.pone.0175290.t003
DAPK1 in bladder cancer
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Fig 5. The association between mRNA expression of DAPK1-associated genes survival in combined bladder cancer cohort.
Kaplan-Meier plots for survival for bladder cancer patients with different levels of mRNA expression of (A) ACOX1, (B) UPK2, (C)
TRAK1, (D) PLEKHG6 and (E) MTX1.
https://doi.org/10.1371/journal.pone.0175290.g005
DAPK1 in bladder cancer
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Fig 6. mRNA expression of TRAK1 in bladder cancer datasets. (A) A scatter plot showing the correlation between the
expression levels of DAPK1 and TRAK1 in bladder cancer dataset GSE13507. (B) A Kaplan-Meier plot for patient survival
DAPK1 in bladder cancer
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expression levels of these genes were measured. As shown in Fig 7B, we found that in T24
cells, ACOX1, TRAK1 and UPK2 were significantly lower in DAPK1 knockdown cells com-
pared to the Scramble control cells. Our results suggest that ACOX1, UPK2 and TRAK1 may
be potential downstream targets of DAPK1.
The identification of small molecules that target DAPK1 gene signature
Among the top 10 small molecules identified by connectivity mapping that can reverse the
DAPK1-associated gene signature (Table 5; the full results of connectivity mapping is listed in
S3 Table), vemurafenib and trametinib have been shown to confer anti-tumor activity in
with different level of TRAK1 expression in bladder cancer dataset GSE13507. (C) A scatter plot showing the correlation
between the expression levels of DAPK1 and TRAK1 in bladder cancer dataset GSE32894. (D) A Kaplan-Meier plot for
patient survival with different level of TRAK1 expression in bladder cancer dataset GSE32894. (E) A scatter plot showing
the correlation between the expression levels of DAPK1 and TRAK1 in bladder cancer dataset GSE48277. (F) A Kaplan-
Meier plot for patient survival with different level of TRAK1 expression in bladder cancer dataset GSE48277.
https://doi.org/10.1371/journal.pone.0175290.g006
Fig 7. In vitro analysis for DAPK1 in bladder cancer. (A) Western blot analysis for DAPK1 in scramble and DAPK1 knockdown T24 cells. (B) Histogram
showing the relative expression of ACOX1, TRAK1 and UPK2 in Scramble and DAPK1 knockdown T24 cells. (C) Histogram showing the relative mRNA
expression of DAPK1 in control or vemurafenib-treated T24 cells. (D) Histogram showing the percentage of cells survived in control and vemurafenib treated
scramble and DAPK1 knockdown T24 cells.
https://doi.org/10.1371/journal.pone.0175290.g007
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melanoma via inhibition of the Braf/MEK/ERK pathway [25–27]. We tested our hypothesis
using T24 cell line and treated it with vemurafenib as Braf is a more upstream component of
the Braf/MEK/ERK pathway, while this molecule has been shown to be an effective treatment
for melanoma patients in a Phase III study [27]. Our results demonstrated that DAPK1 expres-
sion was upregulated by vemurafenib, in line with what we have shown by connectivity map-
ping (Fig 7C). Indeed, from the in vitro analysis, we also found that DAPK1 knockdown T24
cells were less sensitive to treatment of vemurafenib compared to scramble control cells (Fig
7D). Our results suggest that inhibition of Braf may be a potential therapeutic approach for
patients with bladder cancer, while this approach may be more effective in treating bladder
cancer with a high level expression of DAPK1.
Discussion
In this study, we have shown that DAPK1 was downregulated in bladder cancer with high T-
stage in 4 independent bladder cancer patient cohorts (n = 743), each with more than 130
patient specimens, and a low level expression of DAPK1 was correlated with poor prognosis in
3 independent bladder cancer patient cohorts with patient survival status available (n = 462).
Our results suggest that reduced expression of DAPK1 may lead to bladder cancer with a more
aggressive phenotype. In addition, we found that FGFR3 knockdown downregulated DAPK1
in bladder cancer cell line, and TREK1 is coregulated with DAPK1 and a low level expression
of TREK1 was also correlated with poor survival in 3 independent bladder cancer patient
cohorts. Importantly, we identified via connectivity mapping that inhibition of Braf/MEK/
ERK pathway may be a potential therapeutic approach for bladder cancer with reduced expres-
sion of DAPK1.
DAPK1 promoter methylation has been detected in majority of bladder cancer specimens
[11, 13], transcriptional dyeregulation could be one of the major steps for DAPK1 downregula-
tion in bladder cancer. In this study, we have found that DAPK1 mRNA expression was down-
regulated in bladder cancer with high T-stage and with shorter survival time, whether the
downregulation of DAPK1 in these specimens was solely by promoter hypermethylation is
unknown, nonetheless, the results suggest that reduced expression of DAPK1 play an impor-
tant role in bladder cancer progression.
Fibroblast growth factor receptor 3 (FGFR3) has been shown to be a druggable target in
bladder cancer [28], with its activating mutation being associated with recurrence [29]. In the
present study, we have found that DAPK1 was downregulated upon inducible knockdown of
FGFR3 suggesting that DAPK1 may act as a downstream factor of FGFR3 signaling. Although
Table 5. The top 10 small molecules identified via connectivity mapping that could reverse the DAP-
K1-associated gene expression.
Compound p-value Perturb stability
Pronestyl < 0.001 1
Sulfisoxazole < 0.001 1
Protriptyline hydrochloride < 0.001 1
PLX4032 (vemurafenib) < 0.001 1
Furosemide < 0.001 1
Toremifene < 0.001 1
Priscoline < 0.001 0.933
Dantrolene < 0.001 0.933
GSK1120212 (trametinib) < 0.001 0.867
Cefepime hydrochloride < 0.001 0.8
https://doi.org/10.1371/journal.pone.0175290.t005
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we found that in a low FGFR3 expression level background, DAPK1 expression was signifi-
cantly lower in specimens with activating mutation of FGFR3, the results must interpret with
caution since the number of analyzable specimens was relatively small. Further in vitro study
is required to establish the functional role of DAPK1 in FGFR3-activating bladder cancer.
Little is known about the role of TRAK1 in bladder cancer. TRAK1 has been shown to play
a role in endosome-to-lysosome trafficking and GABA(A) receptor homeostasis in hypertonia,
which is observed in human neurological diseases [30, 31]. TRAK1 has been shown to be a
promising diagnostic marker for gastric cancer [32] and a prognostic marker in colorectal can-
cer [33]. In the present study, we have found that TRAK1 was co-regulated with DAPK1 and
was a favorable prognostic marker in bladder cancer. Whether TRAK1 plays a different role
in bladder cancer progression compared to gastric and colorectal cancer should be further
studied.
Mutation of Braf gene in bladder cancer is an infrequent event [34], however, Ras mutation,
which act upstream of Braf, or Ras pathway has been shown to play an important role in blad-
der cancer tumorigenesis [35], while MEK inhibitor, PD-0325901, has been shown to suppress
bladder tumor growth in a patient-derived xenograft model [36] and the inhibition of Raf/
MEK/ERK pathway through Cholera toxin also resulted in growth arrest in cell line model
[37]. In this study, we found that vemurafenib, a Braf inhibitor, and trametinib, a MEK inhibi-
tor, both could reverse DAPK1-associated gene expression signature, by connectivity map-
ping. The results have been further confirmed in a bladder cancer cell line, in which treatment
of vemurafenib resulted in upregulation of vemurafenib. Interestingly, knockdown of DAPK1
in T24 cells led to reduced sensitivity towards vemurafenib. Our results prime others to test
whether DAPK1 expression could be a potential predictive marker for Raf/MEK/ERK pathway
inhibition.
In conclusion, our data show that DAPK1 could be a suppressor in bladder cancer progres-
sion, and suggest that DAPK1 could be a potential biomarker and therapeutic target in bladder
cancer.
Supporting information
S1 Fig. Flow Chart. Extraction of clinical and microarray gene expression data from bladder
cancer patient datasets.
(TIF)
S1 Table. shRNA sequences of scramble and targeting DAPK.
(DOCX)
S2 Table. Summary of Primer Sequences and Product Size Used in the PCR procedure.
(DOCX)
S3 Table. Connectivity Mapping.
(XLSX)
Acknowledgments
HN was in receipt of PhD studentship from the Faculty Health Sciences University of Macau.
Author Contributions
Conceptualization: HFK W-DC YL.
Data curation: S-DZ HFK W-DC YL.
DAPK1 in bladder cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0175290 April 7, 2017 15 / 18
Formal analysis: S-DZ QW HFK.
Funding acquisition: HFK W-DC YL.
Investigation: J-YX P-CC J-LZ Z-SG W-DC YL.
Methodology: J-YX P-CC J-LZ Z-SG.
Project administration: HFK W-DC YL.
Resources: S-DZ HFK W-DC YL.
Software: S-DZ QW.
Supervision: HFK W-DC YL.
Validation: J-YX HN S-DZ QW.
Writing – original draft: J-YX HFK W-DC YL.
Writing – review & editing: J-YX HFK W-DC YL.
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA
Cancer J Clin. 2015; 65(2):87–108. https://doi.org/10.3322/caac.21262 PMID: 25651787
2. Prasad SM, Decastro GJ, Steinberg GD, Medscape. Urothelial carcinoma of the bladder: definition,
treatment and future efforts. Nat Rev Urol. 2011; 8(11):631–42. https://doi.org/10.1038/nrurol.2011.144
PMID: 21989305
3. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment
leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558–62. https://doi.org/
10.1038/nature13904 PMID: 25428503
4. Fahmy O, Khairul-Asri MG, Stenzl A, Gakis G. The current status of checkpoint inhibitors in metastatic
bladder cancer. Clin Exp Metastasis. 2016.
5. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009; 374(9685):239–49. https://doi.
org/10.1016/S0140-6736(09)60491-8 PMID: 19520422
6. Mitra AP. Molecular substratification of bladder cancer: moving towards individualized patient manage-
ment. Ther Adv Urol. 2016; 8(3):215–33. PubMed Central PMCID: PMCPMC4872193. https://doi.org/
10.1177/1756287216638981 PMID: 27247631
7. Singh P, Ravanan P, Talwar P. Death Associated Protein Kinase 1 (DAPK1): A Regulator of Apoptosis
and Autophagy. Front Mol Neurosci. 2016; 9:46. PubMed Central PMCID: PMCPMC4917528. https://
doi.org/10.3389/fnmol.2016.00046 PMID: 27445685
8. Stevens C, Lin Y, Sanchez M, Amin E, Copson E, White H, et al. A germ line mutation in the death
domain of DAPK-1 inactivates ERK-induced apoptosis. J Biol Chem. 2007; 282(18):13791–803. https://
doi.org/10.1074/jbc.M605649200 PMID: 17244621
9. Lin Y, Henderson P, Pettersson S, Satsangi J, Hupp T, Stevens C. Tuberous sclerosis-2 (TSC2) regu-
lates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degrada-
tion pathway. FEBS J. 2011; 278(2):354–70. https://doi.org/10.1111/j.1742-4658.2010.07959.x PMID:
21134130
10. Lin Y, Stevens C, Harrison B, Pathuri S, Amin E, Hupp TR. The alternative splice variant of DAPK-1, s-
DAPK-1, induces proteasome-independent DAPK-1 destabilization. Mol Cell Biochem. 2009; 328(1–
2):101–7. https://doi.org/10.1007/s11010-009-0079-4 PMID: 19267229
11. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, et al. Regularly methylated
novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J
Cancer. 2006; 119(6):1396–402. https://doi.org/10.1002/ijc.21971 PMID: 16642478
12. Neuhausen A, Florl AR, Grimm MO, Schulz WA. DNA methylation alterations in urothelial carcinoma.
Cancer Biol Ther. 2006; 5(8):993–1001. PMID: 16775427
13. Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, et al. Methylation of
tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder
and kidney cancer. Br J Cancer. 2006; 95(12):1701–7. PubMed Central PMCID: PMCPMC2360762.
https://doi.org/10.1038/sj.bjc.6603482 PMID: 17133271
DAPK1 in bladder cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0175290 April 7, 2017 16 / 18
14. Christoph F, Hinz S, Kempkensteffen C, Weikert S, Krause H, Schostak M, et al. A gene expression
profile of tumor suppressor genes commonly methylated in bladder cancer. J Cancer Res Clin Oncol.
2007; 133(6):343–9. https://doi.org/10.1007/s00432-006-0174-9 PMID: 17160380
15. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene
classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010; 9:3. Epub 2010/01/12.
PubMed Central PMCID: PMCPMC2821358. https://doi.org/10.1186/1476-4598-9-3 PMID: 20059769
16. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, et al. Expression signature of E2F1 and its asso-
ciated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010; 28
(16):2660–7. Epub 2010/04/28. https://doi.org/10.1200/JCO.2009.25.0977 PMID: 20421545
17. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, et al. Integrated genomic and gene
expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One. 2012; 7(6):
e38863. Epub 2012/06/12. PubMed Central PMCID: PMCPMC3369837. https://doi.org/10.1371/
journal.pone.0038863 PMID: 22685613
18. Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for
urothelial carcinoma. Clin Cancer Res. 2012; 18(12):3377–86. Epub 2012/05/04. https://doi.org/10.
1158/1078-0432.CCR-12-0077-T PMID: 22553347
19. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal
and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemo-
therapy. Cancer Cell. 2014; 25(2):152–65. Epub 2014/02/15. PubMed Central PMCID:
PMCPMC4011497. https://doi.org/10.1016/j.ccr.2014.01.009 PMID: 24525232
20. Du X, Wang QR, Chan E, Merchant M, Liu J, French D, et al. FGFR3 stimulates stearoyl CoA desatur-
ase 1 activity to promote bladder tumor growth. Cancer Res. 2012; 72(22):5843–55. Epub 2012/09/29.
https://doi.org/10.1158/0008-5472.CAN-12-1329 PMID: 23019225
21. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-
expression signatures to connect small molecules, genes, and disease. Science. 2006; 313
(5795):1929–35. https://doi.org/10.1126/science.1132939 PMID: 17008526
22. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer. 2007; 7(1):54–60.
https://doi.org/10.1038/nrc2044 PMID: 17186018
23. Zhang SD, Gant TW. sscMap: an extensible Java application for connecting small-molecule drugs
using gene-expression signatures. BMC Bioinformatics. 2009; 10:236. PubMed Central PMCID:
PMCPMC2732627. https://doi.org/10.1186/1471-2105-10-236 PMID: 19646231
24. McArt DG, Zhang SD. Identification of candidate small-molecule therapeutics to cancer by gene-signa-
ture perturbation in connectivity mapping. PLoS One. 2011; 6(1):e16382. Epub 2011/02/10. PubMed
Central PMCID: PMC3031567. https://doi.org/10.1371/journal.pone.0016382 PMID: 21305029
25. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobi-
metinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371(20):1867–76. https://doi.org/10.1056/
NEJMoa1408868 PMID: 25265494
26. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved
overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372(1):30–
9. https://doi.org/10.1056/NEJMoa1412690 PMID: 25399551
27. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with
vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507–16. PubMed
Central PMCID: PMCPMC3549296. https://doi.org/10.1056/NEJMoa1103782 PMID: 21639808
28. Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, et al. Tumor heteroge-
neity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications
for perioperative anti-FGFR3 treatment. Ann Oncol. 2016; 27(7):1311–6. https://doi.org/10.1093/
annonc/mdw170 PMID: 27091807
29. Couffignal C, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, Roupret M, et al. The Diagnos-
tic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A
Prospective Multicenter Study. Urology. 2015; 86(6):1185–90. https://doi.org/10.1016/j.urology.2015.
07.036 PMID: 26364695
30. Gilbert SL, Zhang L, Forster ML, Anderson JR, Iwase T, Soliven B, et al. Trak1 mutation disrupts GABA
(A) receptor homeostasis in hypertonic mice. Nat Genet. 2006; 38(2):245–50. https://doi.org/10.1038/
ng1715 PMID: 16380713
31. Webber E, Li L, Chin LS. Hypertonia-associated protein Trak1 is a novel regulator of endosome-to-lyso-
some trafficking. J Mol Biol. 2008; 382(3):638–51. PubMed Central PMCID: PMCPMC2575741. https://
doi.org/10.1016/j.jmb.2008.07.045 PMID: 18675823
32. Zhang F, Ren G, Lu Y, Jin B, Wang J, Chen X, et al. Identification of TRAK1 (Trafficking protein, kine-
sin-binding 1) as MGb2-Ag: a novel cancer biomarker. Cancer Lett. 2009; 274(2):250–8. https://doi.org/
10.1016/j.canlet.2008.09.031 PMID: 18986759
DAPK1 in bladder cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0175290 April 7, 2017 17 / 18
33. An Y, Zhou Y, Ren G, Tian Q, Lu Y, Li H, et al. Elevated expression of MGb2-Ag/TRAK1 is correlated
with poor prognosis in patients with colorectal cancer. Int J Colorectal Dis. 2011; 26(11):1397–404.
https://doi.org/10.1007/s00384-011-1237-1 PMID: 21573901
34. Boulalas I, Zaravinos A, Delakas D, Spandidos DA. Mutational analysis of the BRAF gene in transitional
cell carcinoma of the bladder. Int J Biol Markers. 2009; 24(1):17–21. PMID: 19404918
35. Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, et al. Ras mutation cooperates with beta-cate-
nin activation to drive bladder tumourigenesis. Cell Death Dis. 2011; 2:e124. PubMed Central PMCID:
PMCPMC3101820. https://doi.org/10.1038/cddis.2011.7 PMID: 21368895
36. Cirone P, Andresen CJ, Eswaraka JR, Lappin PB, Bagi CM. Patient-derived xenografts reveal limits to
PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol. 2014; 73
(3):525–38. https://doi.org/10.1007/s00280-014-2376-1 PMID: 24442130
37. Zheng X, Ou Y, Shu M, Wang Y, Zhou Y, Su X, et al. Cholera toxin, a typical protein kinase A activator,
induces G1 phase growth arrest in human bladder transitional cell carcinoma cells via inhibiting the c-
Raf/MEK/ERK signaling pathway. Mol Med Rep. 2014; 9(5):1773–9. https://doi.org/10.3892/mmr.2014.
2054 PMID: 24626525
DAPK1 in bladder cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0175290 April 7, 2017 18 / 18
